Can Breast Milk Cure Cancer? What the Science Says

Drinking breast milk will not cure cancer, and no medical authority recommends it as a treatment. But the claim is not entirely baseless: researchers have identified specific components of human milk that kill tumor cells in laboratory dishes and, in early clinical trials, appear to shrink bladder tumors in patients. The gap between those findings and a cancer cure is enormous, and understanding why requires looking at what breast milk actually contains, what happens when those components meet the human digestive system, and where the science genuinely stands.

The Molecule That Started the Conversation

The story begins with a protein-lipid complex called HAMLET, an acronym for Human Alpha-Lactalbumin Made Lethal to Tumor cells. Alpha-lactalbumin is one of the most abundant proteins in human breast milk. Under normal conditions, it is harmless. But when this protein loses its calcium ion, it unfolds into a looser shape and binds with oleic acid, a fatty acid also present in milk. The resulting complex has a striking property: it kills cancer cells while largely sparing healthy ones.

HAMLET was discovered somewhat accidentally in the 1990s during research on how breast milk affects bacteria. Since then, lab studies have shown that when HAMLET encounters tumor cells, it enters the cell interior, moves to the nucleus, and binds to histones, disrupting how the cell’s DNA is organized. It also targets ribosomes and activates the cell’s self-destruction machinery.¹ The complex appears to exploit features that are conserved across many different cancer types, which is why it works against a broad range of tumor cells in the lab.²

The selectivity is the most intriguing part. Many chemotherapy drugs kill cancer cells effectively but devastate healthy tissue too. HAMLET, in cell culture experiments, preferentially targets tumor cells and leaves differentiated, healthy cells alone. The reasons aren’t fully understood, but researchers believe cancer cells have surface properties and metabolic vulnerabilities that make them especially receptive to HAMLET’s mechanism.

From Lab Dishes to Bladder Cancer Patients

Cell culture results are only the first rung of a very long ladder. The real question is whether HAMLET or anything like it works inside actual human bodies. The most advanced clinical evidence involves a slightly simplified version of the complex called alpha1-oleate, tested in patients with non-muscle-invasive bladder cancer.

In a placebo-controlled, double-blind Phase I/II trial, patients with suspected bladder tumors received either alpha1-oleate or a placebo solution directly into the bladder through a catheter on six occasions over 22 days, before their tumors were surgically removed. The treatment triggered rapid shedding of tumor cells into the urine at every visit. In some cases, entire clusters of tumor tissue broke free. A reduction in tumor size was detected in the treatment group. No drug-related side effects were identified, and healthy bladder tissue showed no signs of damage.³ Follow-up results presented at a major oncology conference confirmed that all primary endpoints for safety and efficacy were met in interim analysis.⁴

These results are genuinely promising, but context matters. The treatment was delivered directly to the tumor surface inside the bladder, not swallowed or injected into the bloodstream. Bladder cancer is one of the few cancer types where you can bathe a tumor in a liquid drug without it needing to survive the digestive system or circulate through the body. Whether HAMLET-like complexes could ever treat cancers in less accessible locations remains an open question.

Why Drinking Breast Milk Is Not the Same Thing

This is where the popular narrative falls apart. Even if HAMLET kills cancer cells in a dish and shows promise when applied directly to bladder tumors, drinking breast milk is a fundamentally different scenario. HAMLET is not simply floating around in fresh breast milk ready to fight tumors. It forms under specific conditions when alpha-lactalbumin loses its calcium and encounters oleic acid in a particular way. The complex has been isolated from the casein fraction of milk under laboratory conditions, and there is evidence it can survive gastric digestion to some degree.⁵ But surviving digestion and reaching a tumor at a therapeutic concentration are two very different things.

Milk proteins in general are broken down in the stomach. Research on gastric digestion of milk proteins shows that digestion efficiency varies with age and processing conditions, but the overall pattern is that proteins are fragmented into shorter peptides as they pass through the gut.⁶ Even if some HAMLET survives the stomach, the amount that would reach the bloodstream intact, travel to a distant tumor, and accumulate at concentrations high enough to kill cancer cells is vanishingly small. The clinical trials used purified, concentrated preparations applied directly to the tumor. That is worlds away from swallowing a glass of breast milk.

The Bovine Equivalent and Oral Prevention

One of the practical limitations of HAMLET is that it comes from human milk, which makes large-scale production difficult. Researchers have developed a bovine analog called BAMLET (Bovine Alpha-Lactalbumin Made Lethal to Tumor cells) using cow’s milk protein and oleic acid. BAMLET has shown its own anticancer effects. In lab studies on colorectal cancer cells with RAS mutations, BAMLET reduced cell viability, blocked a cellular recycling process called autophagy, and pushed cells toward programmed death.⁷

The more remarkable finding involves an animal study where BAMLET was simply added to drinking water. Mice genetically prone to intestinal tumors that received BAMLET orally showed long-term protection against tumor development and reduced expression of genes tied to tumor growth, migration, and blood vessel formation.⁸ BAMLET was also the first version tested in a living bladder cancer model, where it induced cancer cell death and slowed tumor growth in rats.⁹

The oral BAMLET result in mice is interesting because it addresses the digestion objection, at least partly. If BAMLET can prevent intestinal tumors when consumed in water, the complex or its active fragments may be doing something useful in the gut even after partial digestion. But mouse models of cancer are notoriously poor predictors of what works in humans. Many compounds that prevent tumors in genetically engineered mice have failed completely in human trials. This result is a reason to keep studying BAMLET, not a reason to start drinking it.

Making HAMLET Without Milk

A recent development that has generated excitement in the research community involves producing human alpha-lactalbumin in genetically modified plants instead of extracting it from milk. Researchers engineered tobacco plant chloroplasts to manufacture the human protein, then combined it with oleic acid under mild heating conditions to form a HAMLET complex. When tested against human colorectal and breast cancer cell lines, this plant-derived HAMLET was devastatingly effective, reducing viability to less than 8%. In colorectal cancer cells specifically, the viable population dropped to 5%, with the vast majority of cells showing signs of programmed death.¹⁰

This matters for a practical reason: if HAMLET or a related complex ever becomes a real drug, you need a way to produce it at scale. You cannot rely on donated human breast milk to supply a global pharmaceutical. Plant-based biomanufacturing could solve that bottleneck, though these are still very early lab results.

Other Milk Components with Anticancer Properties

HAMLET gets the most attention, but it is not the only component of breast milk that has shown anticancer activity in research settings. Lactoferrin, an iron-binding protein found in both human and cow’s milk, has been studied extensively. In breast cancer cell lines, bovine lactoferrin significantly reduced the ability of cancer cells to invade surrounding tissue and completely shut down the production of survivin, a protein that cancer cells use to resist death.¹¹ Both iron-free and iron-saturated forms of lactoferrin showed activity, though they affected different molecular pathways depending on the cancer cell type.

Breast milk also contains exosomes, tiny membrane-enclosed vesicles that carry proteins, fats, and small RNA molecules called microRNAs. These microRNAs can regulate gene activity in cells that take them up. Research has found that breast milk exosomes are rich in immune-related microRNAs, and investigators have speculated that they could influence gene expression in the infant’s digestive tract.¹² These exosomes have also been explored for their potential roles in immune regulation and inflammation, with some studies noting possible effects on cancer-related pathways. Breastfed children have been found to have a lower prevalence of certain childhood cancers, including acute lymphocytic leukemia and acute myeloid leukemia, and exosomes are one of several candidate explanations for why.

Milk Exosomes as Drug Delivery Vehicles

In a twist that moves the conversation in a completely different direction, some researchers are not interested in milk’s anticancer compounds at all. They are interested in milk’s exosomes as tiny natural packages for delivering existing cancer drugs. Bovine milk can be processed to yield large quantities of exosomes, and because these vesicles are naturally designed to carry cargo through the digestive system, they can be loaded with chemotherapy drugs and survive oral delivery far better than the drugs would on their own.

In one set of experiments, drug-loaded milk exosomes showed significantly higher effectiveness than the same free drug, both in cell culture and against lung tumor grafts in mice. Adding tumor-targeting molecules like folate to the exosome surface further improved cancer-cell targeting and tumor reduction.¹³ Because milk exosomes have membranes with both water-loving and fat-loving components, they can carry a wide range of drug types, including both traditional chemotherapy agents and newer nucleic-acid-based therapeutics.¹⁴

This line of research treats milk not as a cancer-fighting substance itself, but as a source of packaging technology. The idea of swallowing a cancer drug inside a milk exosome instead of receiving it through an IV drip is appealing, particularly for patients who struggle with the side effects of intravenous chemotherapy. It remains at the preclinical stage.

Breastfeeding and the Mother’s Own Cancer Risk

A separate but frequently confused part of this story involves the well-established link between breastfeeding and reduced cancer risk for the mother. This is not about breast milk treating existing cancer. It is about the act of breastfeeding changing the mother’s biology in ways that lower her odds of developing certain cancers later in life.

The data here are far stronger than anything involving HAMLET. A large body of epidemiological evidence shows that the risk of breast cancer drops by about 4.3% for every 12 months of breastfeeding, on top of a roughly 7% decrease in risk for each birth. For triple-negative breast cancer, one of the most aggressive subtypes, the risk reduction is around 20%. For women carrying BRCA1 gene mutations, who face very high lifetime breast cancer risk, breastfeeding has been associated with risk reductions ranging from 22% to 55%.¹⁵

The mechanisms behind this protection are biological, not nutritional. Breastfeeding suppresses ovulation, which reduces cumulative exposure to estrogen, a hormone that fuels many breast cancers. It also appears to promote the shedding of cells with damaged DNA through milk production and may lower insulin levels, which in turn reduces insulin-like growth factor, a molecule that helps cancer cells grow and resist death.¹⁶ An umbrella review of multiple meta-analyses confirmed negative correlations between breastfeeding and several maternal cancers beyond breast cancer.

This is important context because the breastfeeding-cancer connection sometimes gets garbled into the claim that breast milk fights cancer. The protective effect is real, but it operates on the mother’s body through hormonal and cellular mechanisms during lactation. It has nothing to do with consuming the milk.

Breast Milk and Immune Responses to Tumors

One area of research that blurs the line between these stories involves how breast milk interacts with immune cells in the presence of cancer. In laboratory experiments, breast milk influenced macrophages (immune cells that can either promote or suppress tumors depending on their activation state) in ways that shifted them toward a more anti-tumor profile. Macrophages exposed to breast cancer cells that had been pre-treated with breast milk showed increased expression of inflammatory signals associated with tumor fighting and reduced expression of signals associated with the immune-suppressive state that tumors exploit to evade destruction.¹⁷

This research was conducted in the specific context of postpartum breast cancer, a form of breast cancer that develops during or shortly after pregnancy. The findings are mechanistically interesting but very preliminary and limited to in vitro conditions. They do not suggest that breast milk can be used therapeutically against cancer in the general population.

The Risks of Buying Breast Milk Online

Despite the absence of evidence that drinking breast milk treats cancer, an online market has emerged selling human breast milk to adults, with cancer patients among the target customers. This is not a fringe phenomenon. Websites and social media platforms facilitate the sale of unpasteurized breast milk, often shipped without adequate temperature control.

The health risks are real and well-documented. Because this milk is unregulated and unpasteurized, it frequently contains high bacterial loads and potential pathogens, presenting clear infectious disease hazards to consumers.¹⁸ For a cancer patient whose immune system may already be compromised by chemotherapy or the disease itself, consuming unscreened human milk from a stranger introduces risks of bacterial infection, viral transmission, and chemical contaminants with no demonstrated therapeutic upside. No cancer center or oncology guideline endorses this practice.

What HAMLET Research Means for Preterm Infants

An underappreciated angle involves what HAMLET might be doing inside the bodies it was designed for: newborns. Research has explored the presence of cytotoxic alpha-lactalbumin-oleic acid complexes in the milk diet of preterm infants. The complex has specific toxicity not only to cancer cell lines but also to immature, non-transformed cells, and it can trigger inflammatory pathways through the same signaling routes it uses against tumors. In premature infants with immature intestinal tissue, this raises questions about whether HAMLET-like complexes could trigger inflammation with unknown consequences in the developing gut.¹⁹

This is a reminder that biological complexity cuts both ways. The same properties that make HAMLET interesting as a potential cancer therapy could have unintended effects in vulnerable populations. Breast milk evolved to nourish infants, not to serve as a precision oncology drug, and treating it as one oversimplifies the biology in ways that could cause harm.